Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses

Journal of Clinical Psychiatry

Volumn 60, Issue 11, 1999, Pages 783-791

  Melkersson, Kristina I ^a   Hulting, Anna Lena ^b   Brismar, Kerstin E ^b  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; INSULIN; NEUROLEPTIC AGENT; PERPHENAZINE; SOMATOMEDIN C; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; BODY MASS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENCE; INSULIN RELEASE; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 0032708239     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n1112     Document Type: Article

References (49)

1. Brady KT. Weight gain associated with psychotropic drags. South Med J 1989;82:611-617
2. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149: 689-690
3. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72
4. Goff DC, Shader RI. Non-neurological side effects of antipsychotic agents. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell Science; 1995:566-584
5. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472
6. 2C serotonin receptors. Nature 1995;374:542-546
7. 2C receptor antagonist. Neuropharmacology 1997;36:621-629
8. Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol 1988;11(1, suppl):194-206
9. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(9, suppl B):157-160
10. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994; 151:1395
11. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment [letter]. Am J Psychiatry 1994;151:1520-1521
12. Short JA, Nolan JA. Neuroleptic malignant syndrome and hyperosmolar, non-ketotic hyperglycaemic coma. Pract Diabetes Int 1995;12:138-139
13. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment [letter]. Am J Psychiatry 1996;153:737-738
14. Kostakoglu AE, Yazici KM, Erbas T, et al. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996;93:217-218
15. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111
16. Wirshing DA. Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
17. Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299
18. Hartman ML. Physiological regulators of growth hormone secretion. In: Juul A, Jorgensen JOL, eds. Growth Hormone in Adults: Physiological and Clinical Aspects, 1st ed. New York, NY: Cambridge University Press; 1996:5-35,48-106,201-219
19. Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand (suppl) 1991;372:107-114
20. Powell DR, Lee PDK, Suwanichkul A. Similarities in the regulation of HIGFBP-1 and PEPCK gene expression. In: Baxter RC, Gluckman PD, Rosenfeld RG, eds. The Insulin-Like Growth Factors and Their Regulatory Proteins. Amsterdam, the Netherlands: Elsevier; 1994:141-150
21. Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res 1995;6:449-456
22. Rosen T. Growth hormone deficiency in adults [thesis]. Gothenburg, Sweden: University of Gothenburg; 1993
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
24. Grill V, Pigon J, Hartling SG, et al. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high responders. Metabolism 1990;39:251-258
25. Bang P, Eriksson U, Sara V, et al. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-1 as radioligand. Acta Endocrinol (Copenh) 1991;124:620-629
26. Hilding A, Hall K, Wivall-Helleryd I-L, et al. Serum levels of insulin-like growth factor I (IGF-1) in 152 patients with growth hormone (GH) deficiency aged 19-82 years in relation to healthy subjects. J Clin Endocrinol Metab 1999;84:2013-2019
27. Povoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984;107:563-570
28. Labhart A. Classification of diabetes mellitus. In: Thorn GW, Assal JP, eds. Clinical Endocrinology: Theory and Practice. Berlin, Germany: Springer-Verlag; 1986:775-777
29. Tuninger E, Axelsson R, Levander S. A 3-year study of maintenance therapy with depot neuroleptics: clinical characteristics and medication at study entry. Nord J Psychiatry 1994;48:409-417
30. Tuninger E. Depot neuroleptic maintenance treatment: clinical, pharmacological and neuropsychological aspects [thesis], Lund, Sweden: University of Lund; 1997
31. Eggert Hansen C, Rosted Christensen T, Elley J, et al. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 1976;3:915-923
32. Forsman A, Ohman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res 1977;21:396-411
33. Jorgensen A. Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF, eds. Progress in Drug Metabolism, vol 9. New York, NY: Taylor & Francis; 1986:111-174
34. Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 1976;33:858-861
35. Nilsson LB. Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J Chromatogr 1990;526: 139-150
36. Yasui N, Tybring G, Otani K, et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997;7:369-374
37. Llerena A, Alm, C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-97
38. Larsson M, Forsman A. A high-performance liquid chromatographic method for the assay of perphenazine and its dealkylated metabolite in se-rum after therapeutic doses. Ther Drug Monit 1983;5:225-228
39. Dahl ML, Ekqvist B, Widen J, et al. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991;84:99-102
40. Brismar K, Grill V, Efendic S, et al. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 1991;40:728-732
41. Hilding A, Brismar K, Degerblad M, el al. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995;80: 2646-2652
42. Hellenius ML, Brismar KE, Berglund BH, et al. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. J Intern Med 1995;238:121-130
43. Larsson O, Kindmark H, Branstrom R, et al. Perorala antidiabetikas verkningsmekanism. Lakartidningen 1997;94:4473-4477
44. + channel. Eur J Pharmacol 1991; 198:101-104
45. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968;124:978-982
46. Dagli AJ. Severe hyperglycaemia following ingestion of chlorpromazine [letter]. J Assoc Physicians India 1984;32:762-763
47. Ghaeli P, Dufresne RL. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy 1995;15:382
48. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-2081
49. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 1996;19:387-389